Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates

Fig. 2

BLS altered tumors demonstrate disproportionally high neoantigen rates consistent with lack of immunoediting. a) TMB and neoantigen load across predicted binding affinity cutoffs in 4 cancer types. Type I BLS altered tumors demonstrated higher TMB and higher neoantigen rates across all cutoffs applied: 50 nM (NEO50), 100 (NEO100), 250 nM (NEO250), 500 nM (NEO500). b) Proportion of neoantigens carrying genes with ω (dN/dS ratio) < 1 between Type I BLS altered tumors and the Normal samples. dN/dS based on missense mutations and nonsense mutations were separately calculated and shown. Error bars show the 95% confidence interval

Back to article page